Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Apr;35(4):343–348. doi: 10.1111/j.1365-2125.1993.tb04149.x

Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function.

N D Sturrock 1, A D Struthers 1
PMCID: PMC1381543  PMID: 8485013

Full text

PDF
343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Howie A. J., Michael J., McConkey B., Bacon P. A., Adu D. Non-steroidal anti-inflammatory drugs and renal failure. Lancet. 1986 Jan 11;1(8472):57–60. doi: 10.1016/s0140-6736(86)90714-2. [DOI] [PubMed] [Google Scholar]
  2. Arisz L., Donker A. J., Brentjens J. R., van der Hem G. K. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand. 1976;199(1-2):121–125. doi: 10.1111/j.0954-6820.1976.tb06701.x. [DOI] [PubMed] [Google Scholar]
  3. Björck S., Mulec H., Johnsen S. A., Nyberg G., Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ. 1990 Apr 7;300(6729):904–907. doi: 10.1136/bmj.300.6729.904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brezin J. H., Katz S. M., Schwartz A. B., Chinitz J. L. Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1979 Dec 6;301(23):1271–1273. doi: 10.1056/NEJM197912063012306. [DOI] [PubMed] [Google Scholar]
  5. Carmichael J., Shankel S. W. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 1985 Jun;78(6 Pt 1):992–1000. doi: 10.1016/0002-9343(85)90223-2. [DOI] [PubMed] [Google Scholar]
  6. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clive D. M., Stoff J. S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984 Mar 1;310(9):563–572. doi: 10.1056/NEJM198403013100905. [DOI] [PubMed] [Google Scholar]
  9. Cook J., Daneman D., Spino M., Sochett E., Perlman K., Balfe J. W. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr. 1990 Jul;117(1 Pt 1):39–45. doi: 10.1016/s0022-3476(05)82441-2. [DOI] [PubMed] [Google Scholar]
  10. Donker A. J., Arisz L., Brentjens J. R., van der Hem G. K., Hollemans H. J. The effect of indomethacin on kidney function and plasma renin activity in man. Nephron. 1976;17(4):288–296. doi: 10.1159/000180733. [DOI] [PubMed] [Google Scholar]
  11. Donker A. J., Brentjens J. R., van der Hem G. K., Arisz L. Treatment of the nephrotic syndrome with indomethacin. Nephron. 1978;22(4-6):374–381. doi: 10.1159/000181478. [DOI] [PubMed] [Google Scholar]
  12. Dzau V. J., Ingelfinger J. R. Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. J Hypertens Suppl. 1989 Sep;7(7):S3–S8. doi: 10.1097/00004872-198909007-00002. [DOI] [PubMed] [Google Scholar]
  13. Fettman M. J., Wilke W. L. Captopril or prostaglandin E1 ameliorate adverse renal hemodynamic effects of indomethacin in uninephrectomized rats. Toxicol Appl Pharmacol. 1989 Mar 15;98(1):31–38. doi: 10.1016/0041-008x(89)90131-2. [DOI] [PubMed] [Google Scholar]
  14. Giles T. D., Katz R., Sullivan J. M., Wolfson P., Haugland M., Kirlin P., Powers E., Rich S., Hackshaw B., Chiaramida A. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989 May;13(6):1240–1247. doi: 10.1016/0735-1097(89)90294-5. [DOI] [PubMed] [Google Scholar]
  15. Gluck S. L., Klahr S. Enlarging our view of the diabetic kidney. N Engl J Med. 1991 Jun 6;324(23):1662–1664. doi: 10.1056/NEJM199106063242310. [DOI] [PubMed] [Google Scholar]
  16. Golbetz H., Black V., Shemesh O., Myers B. D. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am J Physiol. 1989 Jan;256(1 Pt 2):F44–F51. doi: 10.1152/ajprenal.1989.256.1.F44. [DOI] [PubMed] [Google Scholar]
  17. Hackenthal E., Paul M., Ganten D., Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev. 1990 Oct;70(4):1067–1116. doi: 10.1152/physrev.1990.70.4.1067. [DOI] [PubMed] [Google Scholar]
  18. Hall J. E., Coleman T. G., Guyton A. C. The renin-angiotensin system. Normal physiology and changes in older hypertensives. J Am Geriatr Soc. 1989 Aug;37(8):801–813. doi: 10.1111/j.1532-5415.1989.tb02245.x. [DOI] [PubMed] [Google Scholar]
  19. Heeg J. E., de Jong P. E., Vriesendorp R., de Zeeuw D. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol. 1990;10 (Suppl 1):94–97. doi: 10.1159/000168201. [DOI] [PubMed] [Google Scholar]
  20. Heeg J. E., de Jong P. E., de Zeeuw D. Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action. Clin Sci (Lond) 1991 Sep;81(3):367–372. doi: 10.1042/cs0810367. [DOI] [PubMed] [Google Scholar]
  21. Holdaas H., Hartmann A., Lien M. G., Nilsen L., Jervell J., Fauchald P., Endresen L., Djøseland O., Berg K. J. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med. 1991 Feb;229(2):163–170. doi: 10.1111/j.1365-2796.1991.tb00325.x. [DOI] [PubMed] [Google Scholar]
  22. Horton R., Zipser R., Fichman M. Prostaglandins, renal function and vascular regulation. Med Clin North Am. 1981 Jul;65(4):891–914. doi: 10.1016/s0025-7125(16)31504-8. [DOI] [PubMed] [Google Scholar]
  23. Hricik D. E., Browning P. J., Kopelman R., Goorno W. E., Madias N. E., Dzau V. J. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983 Feb 17;308(7):373–376. doi: 10.1056/NEJM198302173080706. [DOI] [PubMed] [Google Scholar]
  24. Johnston C. I. Biochemistry and pharmacology of the renin-angiotensin system. Drugs. 1990;39 (Suppl 1):21–31. doi: 10.2165/00003495-199000391-00005. [DOI] [PubMed] [Google Scholar]
  25. Kimberly R. P., Bowden R. E., Keiser H. R., Plotz P. H. Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med. 1978 May;64(5):804–807. doi: 10.1016/0002-9343(78)90520-x. [DOI] [PubMed] [Google Scholar]
  26. Koopmans P. P., van Megen T., Thien T., Gribnau F. W. The interaction between indomethacin and captopril or enalapril in healthy volunteers. J Intern Med. 1989 Sep;226(3):139–142. doi: 10.1111/j.1365-2796.1989.tb01370.x. [DOI] [PubMed] [Google Scholar]
  27. Marre M., Leblanc H., Suarez L., Guyenne T. T., Ménard J., Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed) 1987 Jun 6;294(6585):1448–1452. doi: 10.1136/bmj.294.6585.1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mason N. A. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990 May;24(5):496–505. doi: 10.1177/106002809002400511. [DOI] [PubMed] [Google Scholar]
  29. Mimran A., Brunner H. R., Turini G. A., Waeber B., Brunner D. Effect of captopril on renal vascular tone in patients with essential hypertension. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):421s–423s. doi: 10.1042/cs057421s. [DOI] [PubMed] [Google Scholar]
  30. Mimran A., Ribstein J., DuCailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens. 1991 Jan;4(1 Pt 2):7S–14S. doi: 10.1093/ajh/4.1.7s. [DOI] [PubMed] [Google Scholar]
  31. Nasjletti A., Malik K. U. Interrelationships among prostaglandins and vasoactive substances. Med Clin North Am. 1981 Jul;65(4):881–889. doi: 10.1016/s0025-7125(16)31503-6. [DOI] [PubMed] [Google Scholar]
  32. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation. 1988 Jun;77(6 Pt 2):I64–I73. [PubMed] [Google Scholar]
  33. Packer M., Lee W. H., Yushak M., Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986 Oct 2;315(14):847–853. doi: 10.1056/NEJM198610023151402. [DOI] [PubMed] [Google Scholar]
  34. Passmore A. P., Copeland S., Johnston G. D. The effects of ibuprofen and indomethacin on renal function in the presence and absence of frusemide in healthy volunteers on a restricted sodium diet. Br J Clin Pharmacol. 1990 Mar;29(3):311–319. doi: 10.1111/j.1365-2125.1990.tb03641.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Reeves W. B., Foley R. J., Weinman E. J. Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1984 Oct;144(10):1943–1944. doi: 10.1001/archinte.144.10.1943. [DOI] [PubMed] [Google Scholar]
  36. Romanelli G., Giustina A., Bossoni S., Caldonazzo A., Cimino A., Cravarezza P., Giustina G. Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. Diabetes. 1990 Nov;39(11):1333–1338. doi: 10.2337/diab.39.11.1333. [DOI] [PubMed] [Google Scholar]
  37. Romero J. C., Knox F. G. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. State of the art lecture. Hypertension. 1988 Jun;11(6 Pt 2):724–738. doi: 10.1161/01.hyp.11.6.724. [DOI] [PubMed] [Google Scholar]
  38. Rudberg S., Aperia A., Freyschuss U., Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia. 1990 Aug;33(8):470–476. doi: 10.1007/BF00405108. [DOI] [PubMed] [Google Scholar]
  39. Schnermann J., Briggs J. P. Effect of angiotensin and other pressor agents on tubuloglomerular feedback responses. Kidney Int Suppl. 1990 Nov;30:S77–S80. [PubMed] [Google Scholar]
  40. Sedor J. R., Williams S. L., Chremos A. N., Johnson C. L., Dunn M. J. Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clin Pharmacol Ther. 1984 Jul;36(1):85–91. doi: 10.1038/clpt.1984.144. [DOI] [PubMed] [Google Scholar]
  41. Slomowitz L. A., Bergamo R., Grosvenor M., Kopple J. D. Enalapril reduces albumin excretion in diabetic patients with low levels of microalbuminuria. Am J Nephrol. 1990;10(6):457–462. doi: 10.1159/000168169. [DOI] [PubMed] [Google Scholar]
  42. Speirs C. J., Dollery C. T., Inman W. H., Rawson N. S., Wilton L. V. Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure. BMJ. 1988 Oct 1;297(6652):830–832. doi: 10.1136/bmj.297.6652.830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sraer J. D., Kanfer A., Rondeau E., Lacave R. Role of the renin-angiotensin system in the regulation of glomerular filtration. J Cardiovasc Pharmacol. 1989;14 (Suppl 4):S21–S25. [PubMed] [Google Scholar]
  44. Stillman M. T., Napier J., Blackshear J. L. Adverse effects of nonsteroidal anti-inflammatory drugs on the kidney. Med Clin North Am. 1984 Mar;68(2):371–385. doi: 10.1016/s0025-7125(16)31136-1. [DOI] [PubMed] [Google Scholar]
  45. Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H., Ishizaki M., Takahashi H., Sekino H., Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985 Dec 26;313(26):1617–1620. doi: 10.1056/NEJM198512263132601. [DOI] [PubMed] [Google Scholar]
  46. Tiggeler R. G., Hulme B., Wijdeveld P. G. Effect of indomethacin on glomerular permeability in the nephrotic syndrome. Kidney Int. 1979 Sep;16(3):312–321. doi: 10.1038/ki.1979.133. [DOI] [PubMed] [Google Scholar]
  47. Vriesendorp R., Donker A. J., de Zeeuw D., de Jong P. E., van der Hem G. K. Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study. Am J Nephrol. 1985;5(4):236–242. doi: 10.1159/000166941. [DOI] [PubMed] [Google Scholar]
  48. Vriesendorp R., Donker A. J., de Zeeuw D., de Jong P. E., van der Hem G. K., Brentjens J. R. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med. 1986 Aug 25;81(2B):84–94. doi: 10.1016/0002-9343(86)90910-1. [DOI] [PubMed] [Google Scholar]
  49. Weir M. R., Klassen D. K., Hall P. S., Schubert C., Voss T. E., Stromatt S. C., Brown J. A. Minimization of indomethacin-induced reduction in renal function by misoprostol. J Clin Pharmacol. 1991 Aug;31(8):729–735. doi: 10.1002/j.1552-4604.1991.tb03768.x. [DOI] [PubMed] [Google Scholar]
  50. Zeller K., Whittaker E., Sullivan L., Raskin P., Jacobson H. R. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991 Jan 10;324(2):78–84. doi: 10.1056/NEJM199101103240202. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES